Tr1X is developing a novel class of regulatory T cell-based products to cure autoimmune and inflammatory diseases and transform patient lives.
Our novel regulatory T cell-based therapeutics are designed to mimic the function of naturally occurring Type 1 regulatory T (Tr1) cells, an important subset of regulatory cells. Our products work to restore immune tolerance, stopping severe autoimmune and inflammatory diseases in their tracks.The Science
We are combining the latest advances in genetic engineering with decades of T cell biology research to develop scalable, effective cellular therapies targeting inflammation and autoimmunity.
Our cells produce suppressive cytokines in local microenvironments, while preserving protective immune responses.
Our cells are stable and long lived, even in inflammatory environments.
Our cells migrate to sites of inflammation, modulating effector cell responses and inducing de-novo Tr1 cells.
We are pursuing breakthrough innovation in the spaces of autoimmunity and inflammation with a world-class team aiming to change the way devastating diseases are treated.Our Team
We strive to create a collaborative, diverse environment to bring the best out of one another. We are committed to our goals, and to one another, while making sure we enjoy the journey as much as the destination.View Open Positions